Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
More than 40% of patients experienced insomnia, however, the symptoms gradually improved after 3 months
the estimated market size and addressable population for our drug products, including IMCIVREE for the treatment of hypothalamic obesity in Corporate Contact: Head of Investor Relations and Corporate Communications [email protected] Media Contact: Real Chemistry [email protected] Photos accompanying this announcement are available at: Source: Rhythm Pharmaceuticals, Inc.
It depends on the medication and whether blood pressure is controlled
Some individuals are very sensitive to GLP-1 medications and may experience gastrointestinal side effects (nausea, vomiting, and diarrhea)
